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A competitive enzyme-linked immunosorbent assay (C-ELISA) which detects antibodies unique to rinderpest
virus (RPV) has been developed. This test can differentiate antibodies against RPV and those against peste des
petits ruminants virus. The recombinant RPV hemagglutinin (H)-protein C-ELISA (recH C-ELISA) is based
on the ability of a well-characterized monoclonal antibody (MAb) produced with the soluble, secreted form of
the H protein (Sec H protein) of RPV made in a baculovirus expression system to compete with the binding of
RPV antibodies in the serum of vaccinated or infected, recovered animals to the Sec H protein. The B-cell
epitope recognized by the MAb corresponds to amino acids 575 to 583 on the H protein, which is not present
on the antigenically closely related peste des petits ruminants virus hemagglutinin-neuraminidase protein.
Initially, a positive-negative threshold cutoff value for percent inhibition of 34 was established with 500 known
RPV-negative serum samples. The recH C-ELISA was developed with the enzyme immunoassay software of a
commercial RPV C-ELISA kit. Comparative analysis of the test results for 700 serum samples obtained with
the commercial kit gave a sensitivity of 112.4% and a specificity of 72.4%. Variations in percent inhibition
values were observed for the two assay systems. These variations may have been due to the undefined amount
of antigen present in the commercial kit as well as the use of a different MAb. The recH C-ELISA detected more
positive serum samples compared to the number detected by the commercial kit, with the results confirmed by
a virus neutralization test. Thus, recH C-ELISA is a sensitive tool for RPV serosurveillance in disease
eradication programs.
Rinderpest (RP), popularly known as cattle plague, is one of
the oldest known acute and fatal viral diseases of domestic
livestock like cattle, buffaloes, and wild ungulates of the order
Artiodactyla. RP has been eradicated from most parts of the
world by a vigorous policy of vaccination, seromonitoring, and
serosurveillance and by slaughter and segregation programs.
The disease is endemic in some parts of North Africa (south-
ern Somalia and northeastern Kenya), South Asia (Pakistan,
Afghanistan, and Yemen), and the Russian Federation (Amur
region) (from the website of the Emergency Prevention System
for Transboundary Animal and Plant Pests and Diseases, Food
and Agriculture Organization [http://www.fao.org/waicent
/faoinfo/agricult/agr/agah/empres/info/rinderp/pak99.htm]).
RP virus (RPV), the causative agent of RP, is a member of
the genus Morbillivirus in the family Paramyxoviridae. The mor-
billiviruses, which comprise important vertebrate pathogens,
form a closely related and serologically cross-reactive genus.
RPV and peste des petits ruminants virus (PPRV) are two
distinct but antigenically closely related morbilliviruses. PPR
disease is widely distributed in sub-Saharan Africa, the Ara-
bian Peninsula, and the Indian subcontinent (17, 18). Apart
from protecting the bovine population against RPV infection,
PPRV also causes subclinical infection in large ruminants,
which act as carriers of infection to sheep and goats (2). RPV
also infects small ruminants in India, often producing subclin-
ical infection (5). This poses problems in the differentiation of
the two diseases serologically, which is necessary in countries
where both diseases coexist.
Differentiation of RPV and PPRV can be done by using
cDNA probes derived from the nucleocapsid protein gene of
each virus (6), as well as by competitive enzyme-linked immu-
nosorbent assay (C-ELISA) with monoclonal antibodies
(MAbs) directed against proteins of each virus (8). A C-ELISA
which uses a MAb specific for the nucleocapsid protein of RPV
was developed for detection of RPV antibodies in the sera of
cattle and small ruminants (9). Unlike the virus neutralization
test (VNT), the C-ELISA detects RPV-specific antibodies
without showing a cross-reaction. A blocking ELISA method
with two neutralizing MAbs has also been developed for the
detection of PPRV-specific antibodies in caprine and ovine
sera (15). This technique was developed because VNT, the
only available serological test specific for PPRV and the cross-
reactive RPV (14), is time-consuming and unaffordable for
most laboratories in regions where both peste des petits rumi-
nants and RP are endemic.
The surface glycoproteins of RPV induce virus-neutralizing
antibodies in cattle (11, 13, 19), and hence, detection of these
antibodies in sera is a direct measure of the immune status of
the animals that have been vaccinated against or that have
recovered from RPV infection. Since PPRV cross-reacts with
RPV, the use of MAbs against the hemagglutinin (H) protein
of RPV or the hemagglutinin-neuraminidase (HN) protein of
PPRV which recognize a unique epitope on the H or HN
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protein would form the basis of a sensitive, differential sero-
logical test for the seromonitoring of animals for both viral
infections. Anderson and McKay (3) have obtained unique
MAbs and have developed a C-ELISA method for the differ-
ential diagnosis of these two viral infections. However, since
this assay uses crude antigens derived from infected cell ly-
sates, the method suffers from variations in the amount of H
protein made in infected cells in different batches, often lead-
ing to inconsistent results.
In the present work, we have developed a recombinant RPV
H-protein (recH) C-ELISA for RP serosurveillance which uses
an extensively characterized RPV H-protein MAb (12) whose
epitope on the H protein of RPV has been mapped and has not
been found to be present on the PPRV HN protein. A bacu-
lovirus recombinant form of the H protein that does not
anchor to the membrane was used as the antigen to take
advantage of its relative purity, since the protein is secreted in
serum-free medium when it is expressed in insect cells, and its
expression could be maintained at a constant level.
MATERIALS AND METHODS
Cells and viruses. Spodoptera frugiperda 21 (Sf-21) cells were grown in TC-100
insect cell culture medium (Gibco BRL, Gaithersburg, Md.) supplemented with
10% fetal bovine serum (Gibco BRL). Hybridoma cells were cultured in Iscove’s
modified Dulbecco’s medium (Gibco BRL) supplemented with 10% fetal bovine
serum. The method for the generation of a recombinant baculovirus that ex-
pressed the soluble, secreted form of the H protein (Sec H protein) has been
described earlier (11), and the recombinant baculovirus was propagated in Sf-21
cells. Vero cells were cultured in Dulbecco’s modified Eagle’s medium (Himedia,
Mumbai, India) supplemented with 5% fetal calf serum (Gibco-BRL). RPV
(RBOK vaccine strain) was obtained from the Institute of Animal Health and
Veterinary Biologicals, Bangalore, India, and PPRV Nig 75/1 was obtained from
A. Diallo, Centre de coope´ration internationale en recherche agronomique pour
le de´veloppement—De´partement d’e´levage et de me´decine ve´te´rinaire, Monti-
pellier, France; and both of them were propagated on Vero cells.
Serum samples. Sera collected from 1,200 cattle were used in the present
study. Of these, 700 serum samples were from animals that had been more than
4 years old when the sera were collected 2 months after vaccination with an RPV
vaccine and 500 were from heifer calves ages 1 to 2 years that had been born after
RPV vaccination had ceased. All these serum samples and 100 serum samples
collected from sheep 2 months after vaccination were obtained from the national
serum bank facility of the Project Directorate on Animal Disease Monitoring
and Surveillance and were frozen at 20°C.
These serum samples are referred as field serum samples, since the samples
were collected from animals vaccinated in the field during the seromonitoring
phase of the National Project on Rinderpest Eradication and represent samples
from animals from across India.
Preparation of Sec H protein. Sf-21 cells were gradually adapted to serum-free
medium (Sf-900 II SFM; Gibco-BRL). The cells were then infected with the
recombinant baculovirus expressing the Sec H protein (11) at a multiplicity of
infection of 10. The culture supernatant was collected after 72 h when a more
than 90% cytopathic effect was observed. The supernatant was clarified by cen-
trifugation at 4,000  g for 30 min. The Sec H protein was titrated, aliquoted,
freeze-dried, and stored at 20°C until further use in the C-ELISA.
RPV H -protein-specific MAb. An RPV H-protein-specific MAb (MAb D2F4)
was generated by using immunoaffinity-purified Sec H protein. MAb D2F4 maps
to a region from amino acids 575 to 583 on the H protein which is unique to the
RPV H protein and is an immunodominant epitope (12).
Other reagents. An anti-mouse immunoglobulin horseradish peroxidase
(HRP) conjugate was procured from Boehringer Mannheim (Mannheim, Ger-
many); o-phenylenediamine dihydrochloride (OPD) was procured from Sigma
Chemical Co. (St. Louis, Mo.), hydrogen peroxide was procured from Merck,
(Mumbai, India), and 96-well Maxisorp ELISA plates were procured from Nunc
(Roskilde, Denmark).
Reference assay kit. An RPV C-ELISA kit developed at the Institute of
Animal Health (Pirbright, United Kingdom) (3) and marketed by Biologicals
Diagnostic Supplies Ltd. (Ayrshire, United Kingdom) was used as the reference
kit in standardizing the recH C-ELISA. The software provided with the com-
mercial kit was used for analysis of the test results.
Sensitivity and specificity of recH C-ELISA. To calculate the sensitivity and
specificity of the recH C-ELISA, we made use of the results for the 700 serum
samples from vaccinated cattle obtained by both assays. The results obtained
with the commercial kit were considered the “gold standard” (i.e., true positives
and true negatives); and the following formulas were used to determine the
sensitivity and specificity of the recH C-ELISA: sensitivity (number of samples
with positive results by recH C-ELISA/number of true-positive samples)  100,
and specificity  (number of samples with negative results by recH C-ELISA/
number of true-negative samples)  100.
Indirect ELISA. ELISA plates were coated with lysates of Vero cells infected
with RPV RBOK or PPRV Nig 75/1 at a concentration of 1 g/well or with
culture supernatants containing the Sec H protein (5 g/ml; estimated by a
standard method [10]) overnight at 4°C. The plate was washed in phosphate-
buffered saline (PBS) thrice and blocked with blocking buffer (3% bovine gelatin
plus 0.1% Tween 20 in PBS) for 1 h at 37°C. Serial twofold dilutions of the RPV
H protein-specific MAb from ascitic fluid and 1:100 dilutions of PPRV-vacci-
nated sheep sera in PBS were used as the primary antibody, and the plates were
incubated at 37°C for an hour. The plates were then washed, appropriately
diluted anti-mouse whole immunoglobulin HRP and/or anti-goat immunoglob-
ulin HRP were added, and the plates were incubated at 37°C for an hour. The
reaction was developed by using OPD and H2O2, and the reaction was stopped
with 2 N H2SO4. The plates were read at 490 nm in an ELISA reader.
C-ELISA. The recH C-ELISA was performed essentially as described previ-
ously (3). Briefly, the baculovius recombinant Sec H protein of RPV prepared in
serum-free medium was used as the antigen for the C-ELISA. Each well of a
96-well microtiter plate was coated with the antigen (5 g/ml) at 4°C overnight
and treated with blocking buffer (PBS supplemented with 0.1% [vol/vol] Tween
20 and 0.3% [vol/vol] normal bovine serum seronegative for RPV) for 1 h at
37°C. After the plate was washed five times in PBS (0.2 PBS), 50 l of test
serum was added in duplicate at a dilution of 1:100 in blocking buffer to the
respective wells of the plate. Strongly positive, weakly positive, and negative
bovine sera and a MAb with 0% competition were used as controls. MAb control
wells (0% competition) contained antigen, MAb, and enzyme conjugate (no test
serum). Following incubation at 37°C for 1 h on an orbital shaker, the plates were
washed and anti-mouse immunoglobulin HRP conjugate (at a predetermined
dilution) was added. After a final incubation, substrate and chromogen (OPD,
H2O2) were added and the color was allowed to develop for 10 to 15 min. The
absorbance values were read in an ELISA reader at 490 nm and analyzed with
the software for an enzyme immunoassay (Biologicals Diagnostic Supplies Ltd.),
and the optical densities (ODs) were converted to percent inhibition (PI) values
by using the following formula: (100  [OD in test well/OD in 0% competition
well])  100.
Standardization of recH protein C-ELISA reagents and determination of
cutoff PI value. A checkerboard titration was carried out to establish the optimal
working dilutions of antigen, serum, MAb, and immunoconjugate for use in the
recH C-ELISA.
To establish a positive-negative threshold PI value, 500 serum samples from
unvaccinated heifer calves (age, 1 to 2 years old) known to be negative for RPV
were tested by the recH C-ELISA. The mean  2 standard deviation  2 PI
value for these samples was considered the positive-negative cutoff value (16).
Determination of optimal MAb and serum dilutions. Two serum samples (one
strongly positive and one strongly negative) were chosen on the basis of their
reactivities in tests with the reference kit. These sera were obtained as follows:
anti-RPV H-protein-hyperimmune serum was made by injecting a single dose of
recombinant H protein from extracellular RPV (500 g) (11) without adjuvant
into two RPV-seronegative crossbred Holstein  Friesian male calves (age, 1
year). The calves were tested serologically; and after 3 months, when the titer was
high, a large amount of blood was collected and the serum was separated,
aliquoted, and stored at 20°C. This undiluted, hyperimmune serum was con-
sidered the strongly positive serum control. Preimmune sera from the same
calves were used as the negative control. The moderately positive control was
prepared by appropriately diluting the hyperimmune serum in RPV-negative
serum.
It has previously been determined for another morbillivirus C-ELISA (16) and
for the reference kit used in the present study that serum dilutions of 1:10 to 1:20
compete well with the MAb. However, we observed that at a test serum dilution
of 1:100 the recombinant antigen reacted well without background inhibitory
activity. Therefore, for establishment of the optimal MAb dilution, the sera were
tested at a fixed dilution of 1:100 against serial twofold dilutions of MAbs.
Similarly, the optimal serum dilution was determined by testing serial twofold
dilutions of the sera against the optimal MAb dilution. The PI values thus
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generated by the C-ELISA were plotted against the MAb dilution and the serum
dilution. The optimal dilution of each reagent was determined to be the highest
dilution that yielded the maximum differential in PI values between positive and
negative sera.
Comparison of recH C-ELISA and reference kit. The 700 serum samples from
vaccinated animals were tested for the RPV antibody by using both the reference
kit and the newly developed recH C-ELISA. The results of both assays were read
by using the software for an enzyme immunoassay to determine whether each
sample was positive or negative (cutoff PI values, 50 for the reference kit and 34
for the recH C-ELISA).
Field validation of recH C-ELISA. A field validation of the prototype assay was
undertaken by five laboratories, which are located in different states in India.
These laboratories were supplied with the prototype kit containing coded field
bovine serum samples (10 positive and 30 negative) for validation.
Serum neutralization assay. A few of the field test serum samples which were
found to be positive only by the recH C-ELISA and negative with the commercial
RPV C-ELISA kit were tested for their abilities to neutralize RPV (RBOK
strain) infectivity in vitro on Vero cells by a standard VNT method (4). Devel-
opment of a cytopathic effect was monitored by light microscopy, and the titers
were expressed as the reciprocal of the highest dilution of serum which neutral-
ized virus infectivity by 50%.
RESULTS
Optimal dilutions of reagents for recH C-ELISA. The ability
of MAbs to compete with serum antibody depends not only on
the specificities of their binding to antigens but also on the
relative amounts of these reagents in the reaction mixture. It
was thus important to titrate both of these critical reagents to
determine the combination that yielded the best discrimination
between positive and negative control sera. A MAb dilution of
1:5,000 and a test serum dilution of 1:100 were determined to
be optimal. The 1:100 dilution identified RPV-positive and
-negative samples on par with the commercial kit with the least
background activity compared to that obtained with a dilution
of 1:10, which was previously used in a C-ELISA with an
infected cell extract as the antigen (3, 16).
A Sec H protein dilution of 1:150 and an anti-mouse conju-
gate dilution of 1:2,000 were determined to be optimal, while
the control sera was used at a dilution of 1:10, similar to the
dilution used in the reference kit. The control sera used in the
recH C-ELISA were reanalyzed at a dilution of 1:10 by using
the reference kit. The strongly positive serum had a PI value of
84, and the negative serum had a PI value of 10. The moder-
ately positive control serum was prepared by mixing 1 part
anti-RPV H protein immune serum in 3 parts negative serum
and had a PI value of 60.
Determination of cutoff PI value for recH C-ELISA. The
positive-negative cutoff PI value of 34 was arbitrarily set by
adding 2 standard deviations to the mean PI for 500 serum
samples from heifer calves ages 1 to 2 years (Fig. 1).
As our goal was also to differentiate RPV antibodies from
PPRV antibodies, we also screened 100 serum samples from
sheep vaccinated against PPRV (after confirmation of the
presence of PPRV antibodies by indirect ELISA) for the ab-
sence of RPV antibodies by the recH C-ELISA. Use of a cutoff
PI value of 34 also found that all PPRV-positive sera were
negative for RPV antibodies, as desired, due to the unique
MAb to the RPV H protein used as the competing antibody in
the recH C-ELISA. Furthermore, this confirmed that the es-
tablished cutoff PI value of 34 is appropriate for the recH
C-ELISA.
Comparison of commercial C-ELISA kit and recH
C-ELISA. A comparative analysis of the commercial C-ELISA
kit and the recH C-ELISA was carried out to establish diag-
nostic parameters like sensitivity and specificity and to study
the distribution of PI values obtained by both assays, as the
recH C-ELISA uses recombinant antigen and the H-protein
MAb used in the recH C-ELISA is different from that used in
the commercial kit. The results of both assays for 700 serum
samples collected after vaccination indicated that 77.6% of the
animals were serologically positive for RPV antibodies by the
recH C-ELISA, while 69% of the animals were positive by use
of the commercial kit; all 500 serum samples from unvacci-
nated animals were found to be negative by both the assays.
The bar diagram depicting the PI values for the positive serum
samples among the 700 serum samples screened by both assays
indicated that there is a large degree of variation between
these two assays, even though there was little qualitative vari-
ation in the test results (Fig. 2).
The serum neutralization assay was performed with RPV
(RBOK strain)-infected Vero cells and 60 serum samples
which were found to be positive exclusively by the recH C-
ELISA. The results indicated that 45 of the 60 (75%) serum
samples with various VN titers were capable of neutralizing
virus infectivity (Fig. 3), while 8 were unfit for the assay and the
remaining 7 did not neutralize virus infectivity.
DISCUSSION
RPV and PPRV infections occur in ruminant populations in
East Africa, South Asia, sub-Saharan Africa, the Arabian Pen-
insula, and the Middle East (1, 7, 18). Serology is a major
epidemiological tool used to detect RPV and PPRV infections
in ruminant populations, in which the clinical symptoms of
RPV and PPRV infections overlap those caused by the viruses
that cause bovine viral diarrhea in bovines and foot and mouth
disease and blue tongue in sheep and goats. Even virus isola-
tion or confirmation of the presence of antigen is not always
possible because of a lack of sophisticated laboratories to carry
out such tasks.
FIG. 1. Establishment of a positive-negative cutoff point for the
C-ELISA. Each bar represents the PI values for negative serum sam-
ples grouped in classes of 10 samples each. The mean PI value for all
negative serum samples (n 500) was 16 (2 standard deviations) 0.9
 2  34 and was considered the cutoff PI value (vertical dotted line).
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The C-ELISA is a form of indirect ELISA being considered
as the only efficient serological technique that can differentiate
antibodies to antigenically closely related viruses by competi-
tive inhibition of binding of unique epitope-specific MAbs to
the antigen by sera from infected or vaccinated animals. The
versatility of C-ELISA is that it can be applied to antibodies
from any species, and even sera unfit for VNT can be tested.
The availability of a simple, fast, reliable, and inexpensive test
would provide a tool that various laboratories can readily use
for diagnostic and epidemiological purposes. The recH
C-ELISA described in the present work fits that role, and it
also differentiates antibodies induced by RPV from those in-
duced by PPRV.
The antigen (Sec H protein)-coated plates used for the recH
C-ELISA retained their activities even after 1 year, without
any degradation, which solved the inherent problem with the
use of recombinant antigens in diagnostics, which are normally
prone to rapid degradation upon repeated freezing-thawing
and after longer periods of storage. This is the first report of
the use of a baculovirus recombinant secretory antigen pro-
duced in insect cells for diagnostic purposes. As the antigen
used in the assay described here can be quantified, batch-to-
batch variations in the test results do not occur, as has been the
case with the commercial kit, in which an infected cell lysate is
used as the antigen, although its concentrations are not known.
The results obtained by the recH C-ELISA, which uses a cutoff
PI value of 34, and the reference kit, which uses a PI cutoff
value of 50, are comparable. The epitope on the H protein for
the MAb used in this work is from amino acids 575 to 583, is
not present on PPRV HN, and is immunodominant (12). The
uniqueness of the RPV H-protein-specific MAb was proven
serologically by its ability to differentiate RPV antibodies from
PPRV antibodies in the recH C-ELISA.
Even though the results of screening of 1,200 samples by
both assays appear to be almost identical, the PI values for sera
tested by both assays varied from 50 to 98%, which is due to
the nature of the different antigens and the different MAbs
used, which may result in variations in the amount of inhibition
caused by field sera specific for the individual epitopes. Among
the serum samples from vaccinated animals (n  700), the
recH C-ELISA detected larger numbers of animals carrying
RPV antibodies, even when the test serum was diluted 1:100,
compared to the number detected by the commercial kit, which
uses a 1:10 dilution. Field validation of the performance of the
recH C-ELISA in all six laboratories that participated in the
validation of this assay gave consistent results (data not
shown).
The recH C-ELISA detected 8.6% more positive serum
samples than the commercial kit, and this enhanced sensitivity
was further confirmed by selective screening of those 60 addi-
tional positive samples by VNT, which confirmed that 75% of
them were true positives, with the virus neutralization titers
ranging from 10 to 160. However, the actual lineage of the field
virus strain is not known. The recH C-ELISA had a sensitivity
of 112.4% and a specificity of 72.4%.
In order to further prove the efficiency of the recH
C-ELISA, we used 18 serum samples from animals convalesc-
ing from RP from the Department of Biotechnology, Veteri-
nary College, Chennai, India, and found that all of them re-
acted by both assays (the recH C-ELISA and the assay with the
commercial kit). However, the actual lineage or serotype of the
RPV in these serum samples is unknown. Similarly, satisfactory
results were obtained with 38 convalescent-phase serum sam-
ples from animals infected with PPRV.
In conclusion, the recH C-ELISA developed in the present
work could be used globally for RPV serosurveillance purposes
in regions where the National Project on Rinderpest Eradica-
FIG. 2. PI values for serum samples from vaccinated calves (n 
700) screened for the presence or absence of RPV antibodies both by
the recH C-ELISA and with a commercial ELISA kit. Each pair of
bars represents the comparative distributions of PI values obtained by
both assays for only positive serum samples grouped in classes of 10
samples each. The vertical dotted lines represent the cutoff PI values
for the recH C-ELISA and reference C-ELISA (left and right lines,
respectively).
FIG. 3. Bar diagram showing the serum neutralization titers of
RPV-positive serum samples positive by the recH C-ELISA and neg-
ative with the commercial C-ELISA kit.
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tion is still in existence. The task of serosurveillance could be
better accomplished with a well-defined kit, such as the one
described in the present work, along with other assays.
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